Beijing Quality Peptide Biomedical Technology

QL Biopharm, founded in September 2018, is dedicated to the development of biological drugs targeting chronic metabolic diseases such as diabetes, obesity, and NASH. The company specializes in producing recombinant protein drugs using Escherichia coli, with a robust R&D pipeline featuring 10 innovative drugs and biosimilars. Among these, two international first-class innovative drugs and a large-scale biosimilar are set to enter clinical trials by the end of 2022. The R&D team, comprising experts from renowned pharmaceutical companies like Novo Nordisk and Gan Lee, brings extensive experience in biopharmaceuticals. QL Biopharm's ZT002 injection, a first-in-class drug for controlling blood glucose in type 2 diabetes patients, received clinical application approval in April 2023. The company operates in the biopharmaceutical market, focusing on developing and commercializing drugs that address significant unmet medical needs. Revenue is generated through the development and licensing of these drugs. Keywords: biological drugs, chronic diseases, recombinant protein, diabetes, obesity, NASH, clinical trials, Escherichia coli, biosimilars, ZT002 injection.